Eli Lilly and Stock Forecast for 2023 - 2025 - 2030
Updated on 02/01/2023
Eli Lilly and Stock Forecast and Price Target
Based on the current earnings figures, this year's price targets for Eli Lilly and were recently set by twelve distinguished experts, with an average mark of $400.00. If it reached this goal, it would represent a potential upside of approximately 16.23% from the previous closing price in January, 2023. The high end is $440.00, and the low is $202.00. If you're looking for information on Eli Lilly and stock, consider checking out the forecasts for comparable firms such as NasdaqGS:AMGN.
16.23% Upside
Eli Lilly and Fair Value Forecast for 2023 - 2025 - 2030
Eli Lilly and's Price has seen growth In the last two years, going from $128.65 to $173.81 – a gain of 35.10% In the next year, analysts believe that Fair Value will reach $205.97 – an increase of 18.50%. For the next eight years, the forecast is forFair Value to grow by 148.04%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
11
|
$163.42 | $181.05 | 10.45% |
| ABBV Stock Forecast | AbbVie | Outperform |
10
|
$147.74 | $162.12 | 11.68% |
| ROG Stock Forecast | Roche Holding | Outperform |
5
|
CHF293.60 | CHF384.23 | 24.32% |
| AZN Stock Forecast | AstraZeneca PLC | Outperform |
8
|
£10.59k | £153.20 | -98.53% |
| NOVN Stock Forecast | Novartis | Hold |
10
|
CHF85.77 | CHF103.75 | 9.89% |
Eli Lilly and Revenue Forecast for 2023 - 2025 - 2030
Eli Lilly and's Revenue has seen growth In the last two years, going from $22.32B to $28.32B – a gain of 26.88% In the next year, analysts believe that Revenue will reach $30.45B – an increase of 7.54%. For the next eight years, the forecast is forRevenue to grow by 69.31%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| TMO Stock Forecast | Thermo Fisher Scientific Inc | Outperform |
10
|
$570.33 | $618.99 | 8.71% |
| ABT Stock Forecast | Abbott Laboratories | Outperform |
10
|
$110.55 | $116.63 | 13.07% |
| AMGN Stock Forecast | Amgen Inc | Hold |
7
|
$271.73 | $268.00 | 2.31% |
Eli Lilly and Dividend per Share Forecast for 2023 - 2025 - 2030
In the last two years, Dividend per Share for Eli Lilly and has grown by 31.78%, going from $2.58 to $3.40. In the coming year, analysts are expecting an increase in Dividend per Share, predicting it will reach $4.20 – an increase of 23.53%. Over the next eight years, experts anticipate that Dividend per Share growth for Eli Lilly and will be 252.65%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| SAN Stock Forecast | Sanofi | Outperform |
10
|
91.12€ | 108.44€ | 20.72% |
| CSL Stock Forecast | CSL | Outperform |
8
|
$301.85 | $218.60 | -25.11% |
| MRK Stock Forecast | MERCK Kommanditgesellschaft au... | Outperform |
10
|
191.05€ | 209.03€ | 9.92% |
Eli Lilly and Free Cash Flow Forecast for 2023 - 2025 - 2030
In the last two years, Eli Lilly and's Free Cash Flow has increased by 56.49%, going from $3.80B to $5.95B. In the next year, analysts are expecting an increase in Free Cash Flow, predicting it will reach $8.00B – an increase of 34.52%. The Eli Lilly and forecast is for Free Cash Flow to reach $15.12B or grow by 154.09%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| BDX Stock Forecast | Becton, Dickinson and | Outperform |
17
|
$252.22 | $268.00 | 9.03% |
| GSK Stock Forecast | GSK | Hold |
16
|
£1.42k | £16.95 | -98.87% |
| ZTS Stock Forecast | Zoetis | Buy |
18
|
$165.49 | $207.87 | 23.87% |
Eli Lilly and Net Income Forecast for 2023 - 2025 - 2030
In the last two years, Eli Lilly and's Net Income has decreased from $8.32B to $5.58B – a 32.90% drop. In the next year, analysts predict that Net Income will reach $8.82B – an increase of 58.00%. For the next eight years, the forecast is for Net Income to grow by 211.18%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| BAYN Stock Forecast | Bayer | Outperform |
7
|
57.00€ | 74.54€ | 32.46% |
| 4502 Stock Forecast | Takeda Pharmaceutical Company | Outperform |
16
|
¥4.08k | ¥0.00 | 7.84% |
| 4519 Stock Forecast | Chugai Pharmaceutical | Hold |
18
|
¥3.31k | ¥0.00 | 36.03% |
Eli Lilly and EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Eli Lilly and's EBITDA has grown, increasing from $7.23B to $9.73B – an increase of 34.47%. For next year, the 13 analysts predict EBITDA of $11.82B, which would mean an increase of 21.49%. Over the next eight years, the pros' prediction is EBITDAof $20.45B, which would mean a eight-year growth forecast of 110.29%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| ALNY Stock Forecast | Alnylam Pharmaceuticals | Outperform |
7
|
$226.40 | $244.18 | 10.87% |
| 4503 Stock Forecast | Astellas Pharma | Outperform |
18
|
¥1.92k | ¥0.00 | 24.74% |
| BAX Stock Forecast | Baxter International | Outperform |
17
|
$45.69 | $62.83 | 26.94% |
Eli Lilly and EBIT Forecast for 2023 - 2025 - 2030
Eli Lilly and's EBIT has increased by 36.31% In the last two years, going from $6.00B to $8.18B. In the next year, analysts expect EBIT to reach $10.24B – an increase of 25.18%. For the next eight years, the forecast is for EBIT to grow by 143.31%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| 4523 Stock Forecast | Eisai | Hold |
18
|
¥8.15k | ¥0.00 | -18.99% |
| DGX Stock Forecast | Quest Diagnostics | Hold |
10
|
$148.48 | $147.77 | -2.68% |
| 4507 Stock Forecast | Shionogi & | Outperform |
18
|
¥6.44k | ¥0.00 | 36.38% |
Eli Lilly and EPS Price Prediction Forecast for 2023 - 2025 - 2030
Eli Lilly and's EPS has seen growth In the last two years, going from $6.04 to $8.16 – a gain of 35.10% In the next year, analysts believe that EPS will reach $9.67 – an increase of 18.50%. For the next eight years, the forecast is forEPS to grow by 148.04%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| FME Stock Forecast | Fresenius Medical Care AG & Co... | Hold |
18
|
34.39€ | 42.10€ | -6.95% |
| BIM Stock Forecast | bioMérieux | Outperform |
18
|
96.70€ | 105.55€ | 11.17% |
| IPN Stock Forecast | Ipsen | Hold |
17
|
102.20€ | 110.44€ | 5.68% |